Biography for Ryan McBride
Ryan McBride is an award-winning journalist who writes about the life sciences industry. Prior to joining FierceMarkets, he was a freelance journalist and served as a correspondent at Xconomy for more than two years. His stories have appeared in The Boston Globe, the Boston Business Journal, The Motley Fool, and many other publications. In recent years, he has also given guest lectures to graduate students at Boston University’s Center for Science & Medical Journalism. Earlier in his career, he held staff reporter positions at Mass High Tech, Providence Business News, and The Westerly Sun. Ryan enjoys spending time with his family and exploring mountains and beaches in New England. Follow Ryan on Twitter at @RyanMFierce or send him e-mail here.
Articles by Ryan McBride
The rare-disease drug specialist ViroPharma has been generating buyout buzz all week after reports that the company brought on the services of Goldman Sachs to hunt for potential acquisition offers.
Perlmutter has granted a few interviews this month with journalists and analysts, providing some clarity on how the immunologist plans to reshape how Merck prioritizes research of new medicines.
San Diego police say that biotech entrepreneur Hans Petersen shot and wounded his brother-in-law Ron Fletcher and the University of California, San Diego scientist Steven Dowdy at separate times and locations Thursday, The Associated Press reported.
A European Union regulator has recommended approval of 11 new drugs for a range of diseases such as HIV, breast cancer and diabetes. And the nods could lead to final approvals from the European Commission in the coming months.
Martin Shkreli's biotech outfit Retrophin has proposed a buyout of struggling Transcept Pharmaceuticals for $4 per share, but the management of Point Richmond, CA-based Transcept has undertaken a "poison pill" action to keep acquirers at bay.
Agenus has struck a deal to raise about $6.5 million from institutional backers in a direct offering of common stock and warrants. The financing was announced a day after the Lexington, MA-based biotech company revealed that patients with glioblastoma multiforme, a cancer which attacks the brain, who took its experimental vaccine lived more than twice as long without their cancer getting worse than those on the standard of care.
The term "Big Data" sounds mostly like marketing speak to real data scientists, who work with datasets of all sizes to develop applications in healthcare and other sectors. For these data pros, it's about having the right data, not just a lot of data, to make sure they are providing something of value to a customer. Secure a seat now.
Shares of the Calabasas, CA-based biotech outfit shot up more than 25% to $42 midmorning on Tuesday after its Monday release on the results. The promise of ATX-101 could make Kythera a buyout target, an analyst from Cowen & Co. noted, and recommended buying the company's shares.
Eli Lilly has found a new path into the hot rare-disease field. An NIH program has backed the Indianapolis-based drug giant's preclinical-stage research of a potential treatment for a hormone deficiency often caused by a genetic defect.
The company develops drug-delivery platforms that offer therapeutic release of pain medicines while making them difficult to abuse. With the new capital, the company plans to advance one of its two lead opioid treatments, Egalet-001, into late-stage clinical development.